



August 31, 2017

Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress

New Data Reinforce Unmatched Value of the Oncotype DX Breast Recurrence Score® Test to Examine Tumor Biology Across Patient Populations

REDWOOD CITY, Calif., Aug. 31, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four Oncotype DX Breast Recurrence Score® test studies at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference takes place September 8-12 at the IFEMA, Feria de Madrid, in Madrid, in partnership with the European Association for Cancer Research (EACR). Highlights from results that will be presented include:

- | A first-of-its-kind analysis from the National Cancer Institute's population-based SEER Registry evaluating breast cancer-specific survival in young women under 40 years old;
- | First time presentation of a secondary endpoint analysis from the West German Study Group (WSG) PlanB trial, one of the largest contemporary adjuvant breast cancer trials in Europe; and
- | A head-to-head comparison of the most common genomic tests in clinical use for early-stage breast cancer.

The ESMO abstracts are available at www.esmo.org. Following are details for each of the four presentations (all times are in Central European Summer Time):

Saturday, September 9

- | **Abstract:** LBA11
Poster Discussion Session: "Prognostic impact of Recurrence Score (RS), grade/Ki67 central pathological review, and anthracycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results"
Lead Author: Gluz O.
Location: Pamplona Auditorium
Time: 15:05 - 15:25

Sunday, September 10

- | **Abstract:** 1451P
Poster Display: "Breast cancer-specific survival (BCSS) in young woman < 40 years with node negative luminal breast cancer (BC) treated based on tumor gene expression"
Lead Author: Shak S.
Location: Hall 8
Time: 13:15 - 14:15

Monday, September 11

- | **Abstract:** 187P
Poster Display: "Summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene Recurrence Score (RS) assay and other genomic assays for early breast cancer (EBC)"
Lead Author: Varga Z.
Location: Hall 8
Time: 13:15 - 14:15
- | **Abstract:** 192P
Poster Display: "Population sizes of patients (pts) with node negative (N0), HR+, HER2- primary breast cancer (BC), using standard and TAILORx 21-gene Recurrence Score (RS) cut-off values (COV)"
Lead Author: Blohmer J-U.
Location: Hall 8
Time: 13:15 - 14:15

About Oncotype DX®

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 800,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

About Genomic Health

[Genomic Health](http://www.GenomicHealth.com), Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX® gene expression tests that have been used to guide treatment decisions for more than 800,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in [Redwood City](http://www.GenomicHealth.com), California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: [@GenomicHealth](https://twitter.com/GenomicHealth), [Facebook](https://www.facebook.com/GenomicHealth), [YouTube](https://www.youtube.com/GenomicHealth) and [LinkedIn](https://www.linkedin.com/company/GenomicHealth).

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the results of clinical studies; the impact of clinical studies on reimbursement and test adoption; the applicability of clinical study results to actual outcomes; and the commercial performance of the company's tests. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical studies; the impact of clinical studies on reimbursement and test adoption; the applicability of clinical study results to actual outcomes; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, Liquid Select, Genomic Prostate Score, GPS Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-B



View original content with multimedia: <http://www.prnewswire.com/news-releases/genomic-health-continues-to-pioneer-genomic-based-cancer-diagnostics-with-multiple-presentations-at-esmo-2017-congress-300511992.html>

SOURCE Genomic Health, Inc.

News Provided by Acquire Media